[1]李 雪,陈金榆,姜 迪,等.罗替高汀与普拉克索治疗帕金森病的成本效果分析[J].卫生经济研究,2021,38(1):29-34.
　LI Xue,CHEN Jin-yu,JIANG Di,et al.Cost-effectiveness Analysis of Rotigotine and Praxol in Parkinson's Disease Treatment[J].Journal Press of Health Economics Research,2021,38(1):29-34.
点击复制

罗替高汀与普拉克索治疗帕金森病的成本效果分析
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
38
期数:
2021年1期
页码:
29-34
栏目:
成本与费用
出版日期:
2021-01-07

文章信息/Info

Title:
Cost-effectiveness Analysis of Rotigotine and Praxol in Parkinson's Disease Treatment
作者:
李 雪1; 陈金榆1; 姜 迪2; 3; 郭武栋1; 王耀羚1; 赵 琨1
1.国家卫生健康委卫生发展研究中心，北京 100044
2.华中科技大学同济医学院医药卫生管理学院，湖北 武汉 430030
3.湖北省高校人文社科重点研究基地——农村健康服务研究中心，湖北 武汉 430030
Author(s):
LI Xue ;  CHEN Jin-yu ;  JIANG Di ;  GUO Wu-dong ;  WANG Yao-ling ;  ZHAO Kun
Health Development Research Center of the National Health Commission, Beijing 100044,China
关键词:
帕金森病; 成本-效果分析; 罗替高汀; 普拉克索
Keywords:
Parkinson's disease;  cost-effectiveness analysis;  rotigotine;  praxol
分类号:
R956
文献标志码:
A
摘要:
目的：分析罗替高汀与普拉克索（常释剂/缓释剂）治疗帕金森病的成本效果。方法：基于卫生服务体系的角度，根据临床指南中的标准临床路径及H&Y分级，采用动态Markov模型，模拟患者终生的直接医疗成本和质量调整生命年。结果：在治疗帕金森病中，与普拉克索常释剂相比，罗替高汀提高0.062 9个质量调整生命年，费用提高70 361.06元，增量成本效果比为1 118 617.81元/QALY；与普拉克索缓释剂相比，罗替高汀提高0.171 2个质量调整生命年，费用提高52 325.57元，增量成本效果比为305 640.01元/QALY。结论：与普拉克索（常释剂与缓释剂）相比，罗替高汀可以提高帕金森病患者质量调整生命年，同时也增加医疗成本；以世界卫生组织3倍人均GDP 作为判断阈值，对比普拉克索，罗替高汀不具有成本效果。
Abstract:
Objective To analyze the cost-effectiveness of rotigotine and praxol (constant release / sustained release) in Parkinson's disease (PD) treatment.Methods From the point of view of health service system, according to the standard clinical pathway and H&Y classification in clinical guidelines, the dynamic Markov model was used to simulate the direct medical cost and quality adjustment life years of patients.Results In Parkinson's disease treatment , rotigotine was increased by 0.062 9 quality adjusted life years,the cost was increased by 70 361.06RMB,and the incremental cost-effectiveness ratio was 1 118 617.81RMB/QALY, compared with Praxol, sustained-release preparation, rotigotine was increased by 0.171 2 quality-adjusted life years, the cost was increased by 52 325.57 RMB,and the incremental cost-effectiveness ratio was 305 640.01RMB/QALY.Conclusion Compared with praxol (constant release agent and sustained release agent), rotigotine can improve the quality of Parkinson's disease patients, adjust life years, but also increase medical costs. Rotigotine is not cost-effective according to the World Health Organization standard of 3 times per capita GDP as the judgment threshold.

参考文献/References:

[1] 中华医学会神经病学分会帕金森疾病及运动障碍学组.中国帕金森疾病治疗指南（第三版） [J].中华神经科杂志，2014 （6）: 428-433.
[2] De Lau L M L, Breteler M M B. Epidemiology of Parkinson's disease[J].Lancet Neurology,2006,5(6): 525-535.
[3] Alves G,Forsaa E B, Pedersen K F,et al.Epidemiology of Parkinson's disease[J].Journal of Neurology,2008,255:18-32.
[4] Zhang Z X,Roman G C, Hong Z,et al.Parkinson's disease in China:prevalence in Beijing,Xian,and Shanghai[J].Lancet,2005,365(9459):595-597.
[5] Zhang Z X,Shang H F,Hu X,et al.Rotigotine transdermal patch in Chinese patients with early Parkinson's disease:A randomized, double-blind,placebo-controlled pivotal study [J].Parkinsonism Relat Disord,2016,28:49-55.
[6] Zhang Z,Liu C F,Tao E,et al.Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease:A randomized, double-blind, placebo-controlled pivotal study [J].Parkinsonism & Related Disorders, 2017.
[7] Hoehn M M,Yahr M D.Parkinsonism:onset,progression and mortality[J]. Neurology, 1967,17(5):427-442.
[8] Zhang Z X, iu C F,ao E X,et al.Rotigotine transdermal patch in Chinese patients with advanced Parkinson's disease:A randomized, double-blind, placebo-controlled pivotal study[J].Parkinsonism Relat Disord,2017,44:6-12.
[9] Zhang Z X,Shang H F,Hu X,et al.Rotigotine transdermal patch in Chinese patients with early Parkinson's disease:A randomized,double-blind,placebo-controlled pivotal study[J].Parkinsonism Relat Disord, 2016,28:49-55.
[10] Ucb.Mixed Treatment Comparison of Neupro?(rotigotine transdermal system) in Parkinson’s disease,2013.
[11] Ucb. A systematic literature review on the clinical evidence related to the treatment of Parkinson’s disease,2013.
[12] Dams J,Klotsche J,Bornschein B,et al.Mapping the EQ-5D index by UPDRS and PDQ-8 in patients with Parkinson's disease[J]. Health and Quality of Life Outcomes,2013,11.
[13] 中国药物经济学评价指南.中国药物经济学评价指南[J].中国药物经济学,2011.

相似文献/References:

[1]李 雪,姜 迪,陈金榆,等.基于供方视角的我国帕金森病患者直接医疗成本测算[J].卫生经济研究,2021,38(1):26.
　LI Xue,JIANG Di,CHEN Jin-yu,et al.Estimation on Direct Medical Cost of Patients with Parkinson's Disease in China from the Perspective of Suppliers[J].Journal Press of Health Economics Research,2021,38(1):26.
[2]罗慧佳,蓝天骄,潘 杰.低价值医疗服务风险评估研究 ——以子宫切除术为例[J].卫生经济研究,2024,41(01):59.
　LUO Huijia,LAN Tianjiao,PAN Jie.Study on the Risk Assessment of Low-value Care ——An Empirical Analysis of Hysterectomy[J].Journal Press of Health Economics Research,2024,41(1):59.

更新日期/Last Update: 2021-01-07